Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, G.Barekat Pharm's Enterprise Value is IRR0 Mil.
G.Barekat Pharm does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Mar. 2017. Therefore, GuruFocus does not calculate G.Barekat Pharm's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, G.Barekat Pharm's Enterprise Value is IRR0 Mil.
G.Barekat Pharm does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Mar. 2017. Therefore, GuruFocus does not calculate G.Barekat Pharm's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, G.Barekat Pharm's Enterprise Value is IRR0 Mil.
G.Barekat Pharm does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Mar. 2017. Therefore, GuruFocus does not calculate G.Barekat Pharm's EV-to-Revenue at this moment.
G.Barekat Pharm Enterprise Value Historical Data
The historical data trend for G.Barekat Pharm's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
G.Barekat Pharm Enterprise Value Chart
G.Barekat Pharm Annual Data
Trend
Mar16
Mar17
Enterprise Value
-
18,913,898.07
G.Barekat Pharm Semi-Annual Data
Mar16
Mar17
Enterprise Value
-
18,913,898.07
Competitive Comparison of G.Barekat Pharm's Enterprise Value
For the Biotechnology subindustry, G.Barekat Pharm's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
G.Barekat Pharm's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, G.Barekat Pharm's Enterprise Value distribution charts can be found below:
* The bar in red indicates where G.Barekat Pharm's Enterprise Value falls into.
G.Barekat Pharm Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
G.Barekat Pharm's Enterprise Value for the fiscal year that ended in Mar. 2017 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
G.Barekat Pharm (XTEH:BRKT1) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
G.Barekat Pharm Enterprise Value Related Terms
Thank you for viewing the detailed overview of G.Barekat Pharm's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTEH:BRKT1 has been successfully added to your